HCM HUTCHMED (China) (HCM) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001648257
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
24
13F, latest reported quarter
HUTCHMED (China) insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for HUTCHMED (China) Ltd in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
24 funds bought in last quarter
below 65% of Pharma & Biotech
Revenue
-13.0% year over year
below 66% of Pharma & Biotech
Margin
83.3% net margin
more than 97% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.3% of the float short (float per yahoo 2026-10-26) · 5.0 days to cover · settled 2026-09-30
below 92% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HCM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-5.0%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HCM: institutional holders (13F)
13F holdings, latest reported quarter
1,477,494 sh
$15.8M
674,511 sh
$7.3M
582,458 sh
$6.3M
313,611 sh
$3.4M
242,791 sh
$2.7M
Congress trades in HCM
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HCM planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
HCM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Tema Oncology ETF
$776.6K position · as of 2026-05-31
0.4%
Steward Values Enhanced International Fund
$936.0K position · as of 2026-07-31
0.3%
National Security Emerging Markets Index ETF
$86.0K position · as of 2026-05-31
0.2%
Dimensional Emerging Markets Sustainability Core 1 ETF
$14.6K position · as of 2026-07-31
0.0%
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF
$753.9K position · as of 2026-06-30
0.0%
Emerging Markets Sustainability Core 1 Portfolio
$13.8K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 24 funds added last quarter. Each figure is a federal filing, dated the day it went public.
HCM financials
Revenue growth
-13.0%
XBRL, annual
Net margin
83.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$204.9M
four quarters, 2019-01-01 to 2019-12-31
Revenue, TTM HCM
| FY Dec 2025 | $204.9M |
| FY Dec 2024 | $204.9M |
| FY Dec 2023 | $204.9M |
| FY Dec 2022 | $204.9M |
| FY Dec 2021 | $204.9M |
| Dec 2019 | $53.3M |
| Sep 2019 | $49.3M |
| Jun 2019 | $50.0M |
| Mar 2019 | $52.2M |
| Dec 2018 | $53.1M |
| Sep 2018 | $58.8M |
| Jun 2018 | $49.9M |
| Mar 2018 | $52.3M |
At each fiscal year end
Single quarter
Net margin, TTM
-51.7%
net income over revenue, 2019-01-01 to 2019-12-31
Net margin, TTM HCM
| FY Dec 2025 | -51.7% |
| FY Dec 2024 | -51.7% |
| FY Dec 2023 | -51.7% |
| FY Dec 2022 | -51.7% |
| FY Dec 2021 | -51.7% |
| Dec 2019 | -55.4% |
| Sep 2019 | -63.0% |
| Jun 2019 | -50.9% |
| Mar 2019 | -38.1% |
| Dec 2018 | -31.1% |
| Sep 2018 | -43.5% |
| Jun 2018 | -42.0% |
| Mar 2018 | -22.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$89.5M
operating cash flow minus capex, 2019-01-01 to 2019-12-31
Free cash flow, TTM HCM
| FY Dec 2025 | -$89.5M |
| FY Dec 2024 | -$89.5M |
| FY Dec 2023 | -$89.5M |
| FY Dec 2022 | -$89.5M |
| FY Dec 2021 | -$89.5M |
| Dec 2019 | -$20.3M |
| Sep 2019 | -$35.2M |
| Jun 2019 | -$3.6M |
| Mar 2019 | -$30.3M |
| Dec 2018 | -$16.9M |
| Sep 2018 | -$1.7M |
| Jun 2018 | $11.5M |
| Mar 2018 | -$32.2M |
At each fiscal year end
Single quarter
Debt to equity
0.20x
long-term 2019-12-31 plus current 2017-12-31 (24 months older than the period end); equity 2019-12-31
Debt to equity HCM
| FY Dec 2025 | 0.20x |
| FY Dec 2024 | 0.20x |
| FY Dec 2023 | 0.20x |
| FY Dec 2022 | 0.20x |
| FY Dec 2021 | 0.20x |
| Dec 2019 | 0.20x |
| Sep 2019 | 0.00x |
| Jun 2019 | 0.00x |
| Mar 2019 | 0.15x |
| Dec 2018 | 0.15x |
| Sep 2018 | 0.13x |
| Jun 2018 | 0.13x |
| Mar 2018 | 0.06x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.42x
TTM operating cash flow over long-term 2019-12-31 plus current 2017-12-31 (24 months older than the period end)
Cash flow to debt HCM
| FY Dec 2025 | -1.42x |
| FY Dec 2024 | -1.42x |
| FY Dec 2023 | -1.42x |
| FY Dec 2022 | -1.42x |
| FY Dec 2021 | -1.42x |
| Dec 2019 | -1.42x |
| Sep 2019 | n/a |
| Jun 2019 | n/a |
| Mar 2019 | -0.55x |
| Dec 2018 | -0.58x |
| Sep 2018 | n/a |
| Jun 2018 | n/a |
| Mar 2018 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-31.3%
TTM net income over average of 2018-12-31 and 2019-12-31
Return on equity HCM
| FY Dec 2025 | -31.3% |
| FY Dec 2024 | -31.3% |
| FY Dec 2023 | -31.3% |
| FY Dec 2022 | -31.3% |
| FY Dec 2021 | -31.3% |
| Dec 2019 | -31.3% |
| Sep 2019 | -25.2% |
| Jun 2019 | -22.4% |
| Mar 2019 | -19.4% |
| Dec 2018 | -17.6% |
| Sep 2018 | n/a |
| Jun 2018 | n/a |
| Mar 2018 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-21.3%
TTM net income over average of 2018-12-31 and 2019-12-31
Return on assets HCM
| FY Dec 2025 | -21.3% |
| FY Dec 2024 | -21.3% |
| FY Dec 2023 | -21.3% |
| FY Dec 2022 | -21.3% |
| FY Dec 2021 | -21.3% |
| Dec 2019 | -21.3% |
| Sep 2019 | -20.5% |
| Jun 2019 | -16.3% |
| Mar 2019 | -15.4% |
| Dec 2018 | -13.2% |
| Sep 2018 | n/a |
| Jun 2018 | n/a |
| Mar 2018 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital HCM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Dec 2019 | n/a |
| Sep 2019 | n/a |
| Jun 2019 | n/a |
| Mar 2019 | n/a |
| Dec 2018 | n/a |
| Sep 2018 | n/a |
| Jun 2018 | n/a |
| Mar 2018 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-36.7%
operating income (EBIT proxy) over average of 2018-12-31 and 2019-12-31 minus current liabilities
Return on capital employed HCM
| FY Dec 2025 | -36.7% |
| FY Dec 2024 | -36.7% |
| FY Dec 2023 | -36.7% |
| FY Dec 2022 | -36.7% |
| FY Dec 2021 | -36.7% |
| Dec 2019 | -36.7% |
| Sep 2019 | -37.9% |
| Jun 2019 | -25.3% |
| Mar 2019 | -23.7% |
| Dec 2018 | -19.7% |
| Sep 2018 | n/a |
| Jun 2018 | n/a |
| Mar 2018 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing HCM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Dec 2019 | n/a |
| Sep 2019 | n/a |
| Jun 2019 | n/a |
| Mar 2019 | n/a |
| Dec 2018 | n/a |
| Sep 2018 | n/a |
| Jun 2018 | n/a |
| Mar 2018 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$12.5B
market value at close 2026-10-23 on 2025-12-31 shares, plus long-term 2019-12-31 plus current 2017-12-31 (24 months older than the period end), minus cash 2025-12-31
Enterprise value HCM
| FY Dec 2025 | $11.6B |
| FY Dec 2024 | $12.5B |
| FY Dec 2023 | $15.6B |
| FY Dec 2022 | $12.5B |
| FY Dec 2021 | $30.0B |
| Dec 2019 | $16.7B |
| Sep 2019 | $1.1B |
| Jun 2019 | $1.4B |
| Mar 2019 | $2.0B |
| Dec 2018 | $1.5B |
| Sep 2018 | $2.1B |
| Jun 2018 | $2.0B |
| Mar 2018 | $1.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-0.7%
TTM free cash flow over market value at close 2026-10-23
FCF yield HCM
| FY Dec 2025 | -0.8% |
| FY Dec 2024 | -0.7% |
| FY Dec 2023 | -0.6% |
| FY Dec 2022 | -0.7% |
| FY Dec 2021 | -0.3% |
| Dec 2019 | -0.5% |
| Sep 2019 | -7.2% |
| Jun 2019 | -3.6% |
| Mar 2019 | -1.8% |
| Dec 2018 | -2.5% |
| Sep 2018 | n/a |
| Jun 2018 | n/a |
| Mar 2018 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing HCM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Dec 2019 | n/a |
| Sep 2019 | n/a |
| Jun 2019 | n/a |
| Mar 2019 | n/a |
| Dec 2018 | n/a |
| Sep 2018 | n/a |
| Jun 2018 | n/a |
| Mar 2018 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $548.5M | $630.2M | $838.0M | $426.4M |
| Operating income | -$39.2M | -$43.7M | $18.4M | -$407.7M |
| Net income | $456.9M | $37.7M | $100.8M | -$360.8M |
| EPS (diluted) | 0.52 | 0.04 | 0.12 | -0.43 |
| Operating cash flow | -$64.7M | $497.0K | $219.3M | -$268.6M |
| Cash | $71.3M | $154.0M | $283.6M | $313.3M |
| Long-term debt | $68.2M | $59.4M | $48.2M | $18.1M |
| Buybacks | n/a | $36.1M | $9.1M | $48.1M |
SEC XBRL, fiscal years, as known on 2026-10-27
HCM Stock Sonar score 5/7 axes
Find similar shapesCompareHCM ranks highest on risk and compliance (90th percentile) and profitability (65th), and lowest on growth (34th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
